KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Dynavax Technologies (DVAX) over the last 16 years, with Dec 2024 value amounting to $6.4 million.

  • Dynavax Technologies' Capital Expenditures fell 8.10% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 119.60%. This contributed to the annual value of $6.4 million for FY2024, which is 54.78% up from last year.
  • Latest data reveals that Dynavax Technologies reported Capital Expenditures of $6.4 million as of FY2024, which was up 54.78% from $4.1 million recorded in FY2023.
  • In the past 5 years, Dynavax Technologies' Capital Expenditures ranged from a high of $9.5 million in FY2021 and a low of $4.1 million during FY2020.
  • Its 3-year average for Capital Expenditures is $5.9 million, with a median of $6.4 million in 2024.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 81.82% in 2020, then skyrocketed by 132.74% in 2021.
  • Over the past 5 years, Dynavax Technologies' Capital Expenditures (Yearly) stood at $4.1 million in 2020, then surged by 132.74% to $9.5 million in 2021, then decreased by 24.67% to $7.1 million in 2022, then plummeted by 42.51% to $4.1 million in 2023, then spiked by 54.78% to $6.4 million in 2024.